(Voting Panel Chairman)
Throughout his career, Ian has been involved in the quoted growth companies sector. His early career was as a stockbroker, analyst, broadcaster and financial journalist in this area and, since founding The Design Portfolio Marketing Services in 1991, he has been active in helping many companies in this sector with their investor communication and corporate reporting requirements. Ian is also Chairman of Flathill Communications Group plc, President of The Design Portfolio Marketing Services Inc. and a member of the Investor Relations Society.
Renee recently took up a position as CEO of Calliditas Therapeutics AB. She is also a Managing Partner of Positive Capital Partners and was previously a Partner and COO of Omega Funds. Before Omega, she served as a Partner in the Venture Capital group 3i Group plc in London where, since 2005, she was responsible for managing their publicly quoted assets and European legacy healthcare portfolio. In addition, whilst at 3i, Renee structured and executed several secondary sale processes. Prior to this, she was a European Group Head and MD in investment banking. Renee has over twelve years of corporate finance experience with firms such as BT Alex Brown, Deutsche Bank and Lehman Brothers, where she focused on raising M&A and private and public capital for growth companies in both Europe and the US. Prior to investment banking, Renee worked for five years in European sales and marketing for a financial services-focused software business. Renee has a BA in Finance from Stockholm School of Economics and an MBA from INSEAD. She has significant Board experience from both private and public Board work and is presently a Board member of Scibase AB, Simparel Inc and EnXray Limited.
Simon joined FTI from Evolution Securities where he was the Research Analyst responsible for the biotech and small cap healthcare sector. Prior to that Simon spent several years on the buy-side including stints at Millennium Capital and Lehman Brothers as the analyst on global healthcare investment portfolios. Before that he was again on the sell- side as the European Biotech analyst at Bear Stearns. He began his City career at Williams de Broë also as a healthcare analyst. Simon also has first-hand experience of the biotech industry having worked as a scientist at Peptide Therapeutics (Acambis). By profession Simon is a chemist, obtaining his credentials at Imperial College, Cambridge University and Stanford University. His current clients include BTG, Vernalis, GW Pharma, Consort Medical and Verona Pharma.
Victoria joined J.P. Morgan Asset Management in the European Research team covering the Healthcare sector more than ten years ago. She also contributes to the J.P. Morgan Global Healthcare Fund. She became a CFA Charterholder in 2009 and has a BSc in Chemistry from Durham University.
Keno Gutierrez, PhD, MBA, is an Investment Director at M Ventures Healthcare team. He is a Board Member of Inthera Bioscience and iOnctura SA. Prior to joining M Ventures in 2017, he worked at Omega Funds, where he invested in public and private healthcare companies, participating in direct investments and secondaries. Before joining Omega in 2014, Keno was an associate at Piper Jaffray’s Healthcare Investment Banking group, advising biopharma and medtech companies on corporate finance, cross-border M&A and licensing. Prior to joining Piper Jaffray in 2010, he worked as a consultant at IMS Health, advising pharma clients on portfolio strategy and commercial operations. Keno is a Fellow of the Royal Society of Medicine, holds a PhD in Genetics from University College in London and an MBA from INSEAD. His research in lipid metabolism has been published in the top scientific journal Nature. Keno is based in Amsterdam.
Eva has 20 years' experience in fund management and company analysis across the global healthcare sector. She lived in New York for 7 years covering the US. She was recently at Schroder Investment management where she was responsible for the analysis and valuation of publicly listed & about-to-be-listed healthcare companies in medical devices & supplies, diagnostics, biotechnology, pharma, life sciences tools, healthcare distribution, pharmacy benefit management, hospitals & health insurance. Eva has a PhD in Biochemistry from Bristol University. She is also a fluent German speaker.
Anne joined MC Services as Managing Partner in 2011. Prior to this, she held senior management positions in international pharma and biotech companies. Most recently she headed the Investor Relations and Corporate Communications department of Evotec AG for ten years and was a member of the Company’s Executive Committee. Prior to this, she was responsible for investor relations and corporate communications at Schwarz Pharma AG, where she initially held management positions in the International Marketing department. Anne provides over 20 years of experience in international investor and public relations in the biotechnology and pharma sector. She a pharmacist and marketing expert by training.
Tara has a BSc in Biochemistry and a PhD in Structural Biology, both from Imperial College London. She worked with the top-ranked European Healthcare Equity Research team at Lehman Brothers/Nomura. She then moved to Jefferies, where she spent several years as part of the European Biotechnology and Life Sciences Equity Research team. Prior to her role as the Healthcare Analyst at Shore Capital, Tara set up her own life sciences consultancy.
Nick is an experienced Non-executive Director and Chairman with a background as a successful corporate financier. He has considerable experience of businesses in the healthcare, medical, biotechnology, environmental and technology sectors.
Nick is Chairman of SEHTA, one of the largest health technology networking organisations in the UK, Chairman of Interactive Me, a person-centred care business and a Director of Alcuris which is developing an assisted living platform. Until February 2016, Nick was Chairman of Oxford BioMedica plc, a leading gene-based biopharmaceutical company. Until March 2013, Nick was the Chief Executive of Ipso Ventures plc, a creator of, and an investor in, early-stage technology and healthcare businesses. In this capacity he has created eight businesses around university technology.
Julie joined Panmure Gordon in November 2015 from Canaccord Genuity. She has 20 years’ experience in life sciences research, covering both UK and continental European companies across a wide range of healthcare subsectors. These include biotechnology, medical devices, diagnostics and healthcare services across both large and small-cap companies. Prior to Canaccord Genuity, Julie was a member of the No.1 Extel-rated Healthcare team at Piper Jaffray. Julie started her City career at Beeson Gregory, where she became Head of Life Sciences Research. Julie has a PhD in Microbiology from the University of Kent and experience in industry in both Europe and the US. She is also a panel member for NIHR i4i (invention for innovation), assessing early-stage medical technologies.
James has over 20 years of experience of advising UK growth companies with over 12 years dedicated to the healthcare sector. Prior to joining Peel Hunt in 2009, James was a senior banker in Piper Jaffray’s European healthcare IB team with a focus on ECM and M&A mandates.
Gary is an experienced Healthcare Analyst having worked in the City since early 2001. He joined Bryan, Garnier & Co. in September 2017 as Managing Director, UK Healthcare Research. He has been responsible for research coverage of the life sciences sector, including companies active in biotechnology, specialty pharmaceuticals, medical technology and clinical research services. He has been involved with numerous IPOs and M&A mandates in the UK and Europe and has previously worked at Zeus Capital, Nomura Code Securities and KBC Peel Hunt. Prior to becoming an analyst, he managed R&D groups at a Canadian biotech company and before that he was a Postdoctoral Fellow at the Ludwig Institute for Cancer Research, Lausanne Branch, Switzerland. He holds an MBA (University of Durham Business School) and a PhD in Immunology from the Faculty of Medicine, Monash University (Melbourne, Australia).
Mette is Managing Partner in Lundbeckfonden Ventures, an evergreen life science venture fund. Mette has more than 20 years of broad international experience within biotech and life science, covering business development and licensing, management, and financing. She was previously co-founder and CEO of 7TM Pharma. Prior to that she was part of the management team of NeuroSearch A/S responsible for business development and licensing and has, over the years, co-founded several biotech companies. She started her career as a Patent Agent. Mette has been appointed to numerous Board positions both in private and public companies. Mette graduated with a degree in Biology from the University of Copenhagen and also has an MBA.
Vadim has over a decade of capital markets experience, specialising in the healthcare sector. He currently is a Managing Director at Northland Capital Partners, where he established a leading healthcare franchise. Previously he headed the Research department at Daniel Stewart & Co., where he also established a healthcare franchise for the firm. Prior to that, he worked in research and healthcare analysis roles for Economic and Business Data Inc. and Healthcare Information Technologies Inc. Vadim holds a BSc in Microbiology and Immunology and a Master’s degree in Economics from McGill University.
Ailsa joined SVLS in November 2006, as IBT Investment Analyst and became an Investment Manager in 2008, where she is part of the public markets focused team. Previously, Ailsa worked at Baring Asset Management for two years as a research analyst, covering pharmaceutical and biotechnology stocks. Prior to this, Ailsa worked for Insight Investment / Rothschild Asset Management (merged 2003) within the Global/US investment team. Ailsa has a BSc (Hons) in Biology from the University of Manchester. She was awarded the IMC in 2002 and the Securities Institute Diploma in 2007.
Mary-Jane co-founded Consilium in July 2013 having led the management buy-out from M:Communications.
She has more than 20 years of healthcare experience from leading communications agencies and the pharmaceutical industry and is an expert in financial, corporate, investor and scientific communications.
Prior to founding Consilium, Mary-Jane established and led M:Communications’ successful international healthcare team where she advised public and private companies internationally across all sub-sectors of healthcare and including some of the sector’s leading industry bodies. She has extensive experience including advising on a wide range of high profile IPOs, secondary fundraisings, private equity placements, M&A transactions, crisis communications and clinical data and product launches.
Mary-Jane worked both as a scientist and PR/IR executive at PowderJect Pharmaceuticals plc from 1997-2003 and was previously with Bell Laboratories Inc in Madison, Wisconsin, US. Mary-Jane has a BSc (Hons) in BioMedical Sciences.
Dylan van Haaften joined NIBC in 2017 and is responsible for expanding coverage in pan-European Life Sciences. Prior to that Dylan worked as an equity research analyst in the Life Sciences team at the securities division of Kempen & Co, covering the listed Life Sciences and Biochemicals space. Dylan holds an MSc. in Finance from the University of Amsterdam.
Stefan is a Director of Equity Research in the Healthcare & Life Sciences team at Numis, which is currently the No.1 Extel (2017) ranked team in the UK sector. The Numis team provides broad coverage of over 30 UK-listed mid- and small-cap healthcare and life sciences companies including all of the FTSE250-listed companies in the sector, and acts as broker or advisor to around 20 listed and private companies in the sector. Prior to joining Numis in January 2016, Stefan spent five years at Peel Hunt where he helped build the team to achieve the No.1 Extel sector ranking for three years in a row over 2012-14. Stefan has 15 years of experience as an equity analyst and has helped to raise over £2bn for healthcare and life sciences companies. Prior to becoming an analyst, Stefan spent several years in strategy consulting. He has a PhD in antibody engineering from the University of Cambridge and is a CFA charterholder.
Max joined Stifel in September 2013 as Head of European Healthcare Equity Research. Prior to this he was Chief Financial Officer of Silence Therapeutics plc. Max possesses more than 20 years of biotechnology and pharmaceutical industry experience, having held key management positions with leading development-stage companies, as well as establishing several highly rated equity research teams at a number of investment banks.
Max holds a BSc in Microbiology from the University of Kent and qualified as a Chartered Account with Arthur Andersen.
Ed Rayner is an Investment Director in the deal team at Arix Bioscience plc, and Managing Director of Arix’s Arthurian Life Sciences fund management operation. Arix sources, finances and builds life science businesses addressing medical innovation at all stages of development. Headquartered in London and with an office in New York, Arix has made 13 investments since inception two years ago across a range of therapeutic areas.
Before joining Arix at its founding, Ed spent 18 years as an equity analyst and portfolio manager in Europe and Australia. As part of his responsibilities he focused on the healthcare sector, investing in a wide range of bioscience companies. Ed has an MA in Chemistry and MSc in Management for the University of Oxford and is a Chartered Financial Analyst.
Jonathan was previously a Biotech Equity Research Analyst at Credit Suisse (where his team was ranked number one by Institutional Investor) and Evolution. Prior to joining Stifel, he spent six years in corporate finance at Nomura Code. Jonathan’s fundraising experience includes NicOx, GPC Biotech, Actelion, Carmat, Vernalis, Glide Pharma, Ergomed and Rex Bionics. His M&A experience includes the sales of CeNeS, CBT Pharmaceuticals, Biocompatibles International and Protherics. Jonathan is a qualified medical doctor.
Sachin is the Co-founder, promoter and Fund Manager of Third Eye Healthcare Fund. Prior to incorporating Third Eye in 2016, Sachin worked as an Equity Research Analyst on the Life Sciences team in the Securities division of Kempen & Co, a merchant bank in Amsterdam, the Netherlands, before becoming a Director and Head of the Life Sciences team. During his eight years at Kempen & Co from 2008 to 2016, he led a team of five, was responsible for coverage of the European healthcare and life sciences sector and won Extel and Starmine awards for stock picking. He has over ten years of experience in life sciences, with an exposure to both private (Venture Capital) as well as public market investments, and has been involved in multiple IPOs and secondary transactions, raising over €1.0bn for various life sciences companies.
Melanie is a Partner, Life Sciences at Instinctif and she leads on financial communications within the Life Sciences team. She has 20 years of experience advising life sciences companies on financial communications. Prior to joining Instinctif, she built and established the life sciences practice at the Hogarth Partnership. She was a Partner in the Financial Dynamics (now FTI) Life Sciences team and a Director at Merlin Financial PR. She has extensive experience of capital market transactions and corporate issues facing the pharma, biotech, medtech and healthcare industries, as well as advising specialist VC and IP commercialisation companies. Before entering business communications, she was at Price Waterhouse where she qualified as a Chartered Accountant. She has a BA in Biochemistry from the University of Oxford.
Julie is the Managing Director of Design Portfolio and a Director of its parent company, Flathill Communications Group plc. Established for over 25 years, the group provides integrated corporate, marketing and investor communications to businesses ranging from the FTSE350 through to AIM, as well as private companies both in the UK and internationally. Julie has spent nearly 20 years advising corporate clients across a wide range of industry sectors on all aspects of their communication, from annual reports, corporate websites and video through to sustainability communications and branding.